argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
argenx SE (ARGNF) - Net Assets
Latest net assets as of June 2025: $6.10 Billion USD
Based on the latest financial reports, argenx SE (ARGNF) has net assets worth $6.10 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.18 Billion) and total liabilities ($1.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.10 Billion |
| % of Total Assets | 84.95% |
| Annual Growth Rate | 59.97% |
| 5-Year Change | 227.65% |
| 10-Year Change | 14649.4% |
| Growth Volatility | 124.04 |
argenx SE - Net Assets Trend (2014–2024)
This chart illustrates how argenx SE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for argenx SE (2014–2024)
The table below shows the annual net assets of argenx SE from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.50 Billion | +34.19% |
| 2023-12-31 | $4.10 Billion | +45.63% |
| 2022-12-31 | $2.81 Billion | +11.03% |
| 2021-12-31 | $2.53 Billion | +51.02% |
| 2020-12-31 | $1.68 Billion | +59.71% |
| 2019-12-31 | $1.05 Billion | +95.16% |
| 2018-12-31 | $538.39 Million | +56.09% |
| 2017-12-31 | $344.93 Million | +444.28% |
| 2016-12-31 | $63.37 Million | +70.00% |
| 2015-12-31 | $37.28 Million | -25.57% |
| 2014-12-31 | $50.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to argenx SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 153599800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $7.07 Billion | 128.59% |
| Total Equity | $5.50 Billion | 100.00% |
argenx SE Competitors by Market Cap
The table below lists competitors of argenx SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ASE TECHN.HLDG.CO.LTD.
F:2DQ
|
$43.10 Billion |
|
Hess Corporation
NYSE:HES
|
$43.42 Billion |
|
Mercedes-Benz Group AG
PINK:MBGAF
|
$43.59 Billion |
|
Nasdaq Inc
NASDAQ:NDAQ
|
$43.74 Billion |
|
COMPASS GROUP LS-1105
XETRA:XGR2
|
$42.97 Billion |
|
DELL TECHS INC. C DL-01
XETRA:12DA
|
$42.55 Billion |
|
COINBASE GLB.CL.A -00001
F:1QZ
|
$42.51 Billion |
|
Barclays PLC
PINK:BCLYF
|
$42.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in argenx SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,097,507,000 to 5,498,283,000, a change of 1,400,776,000 (34.2%).
- Net income of 833,040,000 contributed positively to equity growth.
- Other factors increased equity by 567,736,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $833.04 Million | +15.15% |
| Other Changes | $567.74 Million | +10.33% |
| Total Change | $- | 34.19% |
Book Value vs Market Value Analysis
This analysis compares argenx SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 46.60x to 7.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $14.97 | $697.42 | x |
| 2019-12-31 | $24.57 | $697.42 | x |
| 2020-12-31 | $35.28 | $697.42 | x |
| 2021-12-31 | $49.05 | $697.42 | x |
| 2022-12-31 | $50.79 | $697.42 | x |
| 2023-12-31 | $69.22 | $697.42 | x |
| 2024-12-31 | $90.49 | $697.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently argenx SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.15%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 38.03%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.13x
- Recent ROE (15.15%) is above the historical average (-18.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -20.59% | -191.82% | 0.09x | 1.17x | $-15.32 Million |
| 2015 | -41.08% | -153.81% | 0.22x | 1.23x | $-19.04 Million |
| 2016 | -33.73% | -124.62% | 0.16x | 1.67x | $-27.71 Million |
| 2017 | -8.14% | -68.05% | 0.11x | 1.08x | $-62.57 Million |
| 2018 | -12.38% | -227.98% | 0.05x | 1.07x | $-120.48 Million |
| 2019 | -15.51% | -197.33% | 0.06x | 1.36x | $-268.04 Million |
| 2020 | -38.77% | -1452.09% | 0.02x | 1.36x | $-818.36 Million |
| 2021 | -16.11% | -82.10% | 0.17x | 1.12x | $-661.69 Million |
| 2022 | -25.22% | -172.76% | 0.13x | 1.11x | $-990.96 Million |
| 2023 | -7.20% | -24.06% | 0.27x | 1.11x | $-704.80 Million |
| 2024 | 15.15% | 38.03% | 0.35x | 1.13x | $283.21 Million |
Industry Comparison
This section compares argenx SE's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| argenx SE (ARGNF) | $6.10 Billion | -20.59% | 0.18x | $42.99 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |